Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIALE-A: Venetoclax + Azacitidine vs Azacitidine in AML Ineligible for Induction (Extension/Continued Access)
2024-513631-25-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Venetoclax + Azacitidine with Azacitidine + Placebo (2 arms). Primary endpoints: Rate of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) and Overall survival (OS). Started Jul 2024; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-513631-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513631-25-00.